I am writing in regard to the recent installment to “Clinical Trials” on Glioblastoma published in The ASCO Post (February 10, 2015, pages 69-71). As a principal investigator, I’d also like to call attention to the following glioblastoma trial, which remains open.
PHASE II
Study Type: Phase I/II/interventional/single-group assignment
Study Title: Phase I/II Prospective Trial for Newly Diagnosed GBM, With Upfront Gross or Subtotal Resection, Followed by Ketogenic Diet With Radiotherapy and Concurrent Temodar Chemotherapy Followed by Adjuvant Temodar Chemotherapy.
Study Sponsor and Collaborators: St. Joseph’s Hospital and Medical Center, Phoenix
Purpose: To determine if reducing blood sugar and increasing ketones can increase survival and enhance the effects of standard radiation and chemotherapy treatments in newly diagnosed glioblastoma multiforme.
Ages Eligible for Study: 18 years and older
Genders Eligible for Study: Both
Accepts Health Volunteers: No
Primary Outcome Measures: Number of participants with adverse events, (time frame: 8 weeks)
Principal Investigator: Adrienne C Scheck, PhD, Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center; adrienne.scheck@
dignityhealth.org
For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT02046187 ■
—Adrienne C. Scheck, PhD
Barrow Brain Tumor Research Center
Phoenix, Arizona
Editor’s note: On an occasional basis, The ASCO Post publishes listings of NCI-supported clinical trials on various tumor types. This list of clinical trials is compiled from information available on ClinicalTrials.gov. It is not meant to be all inclusive, but rather to provide an overview of NCI-funded clinical trials open for recruitment. We invite readers to share information about ongoing NCI-funded clinical trials.
